RCSI and Inflection Biosciences Ltd have announced a research collaboration that aims to examine potential new treatments for patients with a cancer that does not respond effectively to existing therapies. Pictured (l-r) are Professor Bryan Hennessy, Senior Clinical Lecturer at RCSI, Consultant Medical Oncologist in Beaumont Hospital and Our Lady of Lourdes Hospital, Drogheda; Darren Cunningham, Chief Executive Officer at Inflection Biosciences Ltd; and Dr Michael O’Neill, Director of Research and Development at Inflection Biosciences.